Collagen crosslinking provides corneal stability in young patients
September 13, 2021
CXL is safe, effective to perform on younger population, study results show.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Cornea
Study targets utility of epithelial thickness mapping
September 17, 2021
Investigators examine usefulness in refractive surgery evaluations.
What a novel dual-chamber vial brings to corneal preservation
September 07, 2021
Researchers believe the vial has the potential to transform the way corneal grafts are preserved and will provide scientists with a platform to develop customized preservation solutions.
Targeting the utility of epithelial thickness mapping
August 30, 2021
Investigators examine usefulness in refractive surgery evaluations
Examining 10-year postop data on epi-off CXL for keratoconus, ectasia
August 28, 2021
Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.
Dry eye patients reveal misconceptions about condition in new survey
August 20, 2021
A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.
The benefits of cryopreserved amniotic membrane during COVID-19
August 17, 2021
CAM’s regenerative healing means long-term relief and fewer visits to clinic.
Aurion Biotech: Treating endothelial disease with one donor
August 13, 2021
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
VA and visual function go the way of ocular inflammation
August 12, 2021
Tool for quantifying measures may predict outcomes for patients.
FDA grants clearance for myopia device
August 10, 2021
According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.